Literature DB >> 11300963

Unsafe injecting practices among attendees of syringe exchange programmes in France.

M Valenciano1, J Emmanuelli, F Lert.   

Abstract

AIMS: To describe syringe exchange programme attendees and their injection practices.
DESIGN: Cross-sectional study (one week in 1998). Data were collected through a standardized questionnaire.
SETTING: 60/74 syringe exchange programmes (SEPs) in France. PARTICIPANTS: Clients requesting syringes in 60 SEPs. MEASUREMENTS: Self-reports of drug use, injecting behaviour, sexual behaviour, serological status (HIV, HBV, HCV). Prevalence of unsafe injecting practices in the previous month such as: syringe sharing; and sharing other injection paraphernalia.
FINDINGS: 1004 questionnaires were collected (response rate: 50%). The mean age of respondents was 30 years, and 70% were males. Among individuals tested, HIV reported prevalence was 19.2%, HCV 58.4% and HBV 20.8%. The mean duration of drug use was 11 years. Eighty-five percent were polydrug users and buprenorphine high-dosage was the substance most used (73%). In the previous month, 45% of the participants had re-used a syringe, 93% injected at least daily (mean 3.6 injections per day), 18% shared a syringe and 71% shared injection paraphernalia. In multivariate analyses, unsafe injecting practices were associated with heroin and cocaine use and with living in a couple. The cluster analysis identified five categories of IDUs: users of buprenorphine-HD (45% of the responders), morphine-sulphate (17%), benzodiazepines and other legal drugs (13%), methadone associated with other legal drugs (13%) and crack-cocaine (13%). The buprenorphine-HD group had better social status and safer injection practices.
CONCLUSIONS: In France, despite an increase in the accessibility to syringes and substitution treatments, unsafe injecting practices persist among SEP attenders. Interventions should stress the importance of using sterile material for each injection, even with a steady sex partner.

Entities:  

Mesh:

Year:  2001        PMID: 11300963     DOI: 10.1046/j.1360-0443.2001.9645978.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  8 in total

1.  Buprenorphine-related deaths: unusual forensic situations.

Authors:  Anne-Laure Pelissier-Alicot; Caroline Sastre; Valerie Baillif-Couniou; Jean-Michel Gaulier; Pascal Kintz; Erika Kuhlmann; Pierre Perich; Christophe Bartoli; Marie-Dominique Piercecchi-Marti; Georges Leonetti
Journal:  Int J Legal Med       Date:  2010-04-06       Impact factor: 2.686

2.  Unsafe injection and sexual risk behavior among injecting drug users in Georgia.

Authors:  Ivdity Chikovani; Ivana Bozicevic; Ketevan Goguadze; Natia Rukhadze; George Gotsadze
Journal:  J Urban Health       Date:  2011-08       Impact factor: 3.671

Review 3.  Why buprenorphine is so successful in treating opiate addiction in France.

Authors:  M Fatseas; Marc Auriacombe
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

4.  Identifying heterogeneity among injection drug users: a cluster analysis approach.

Authors:  Souradet Y Shaw; Lena Shah; Ann M Jolly; John L Wylie
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

Review 5.  HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks.

Authors:  Don C Des Jarlais; Thomas Kerr; Patrizia Carrieri; Jonathan Feelemyer; Kamyar Arasteh
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

6.  Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention.

Authors:  Mark A Stoové; Craig L Fry; Nicholas Lintzeris
Journal:  Harm Reduct J       Date:  2008-04-23

Review 7.  Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Authors:  Nikki Bozinoff; Vitor Tardelli; Dafna Sara Rubin-Kahana; Bernard Le Foll
Journal:  Harm Reduct J       Date:  2022-10-13

8.  Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002.

Authors:  Estelle Lavie; Mélina Fatséas; Jean-Pierre Daulouède; Cécile Denis; Jacques Dubernet; Laurent Cattan; Marc Auriacombe
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.